Signal from the log
Convergen
15 M$ · Early stage · China · Biotech
Convergen, à Suzhou, conçoit des dégradeurs de protéines fondés sur TRIM21 pour éliminer les agrégats protéiques en cause dans les maladies neurodégénératives et auto-immunes. Le tour porte à 25 M$ le total levé depuis la création.
Verified
Announced on , logged by the watch of 31 August 2026.
- Operation
- Funding round
- Announced amount
- 15 M$
- Stage
- Early stage
- Country
- China
- Sector
- Biotech
What the log says
Editorial note, in French
Communiqué ouvert, montant relu et fonds nommés.
The investors
Led by MPCi , with LAV , BioTrack Capital
Provenance
Source prnewswire
Logged on 31 August 2026
Description Written in French during the watch run. Written during the watch run, after reading the issuer's press release or the source article.
Verification Amounts and fund names were double checked against the issuer's press release or an official filing.
What this status means
Verified The press release was opened: amount double checked, funds named. The article remains to be written.
The rule A signal is never removed from the log. A round set aside stays readable with its reason, because a collection you cannot reread is a collection you cannot correct.